[PRIVATE & CONFIDENTIAL Our Ref: SCH 1623/SS/KK/A18/CH0589/16 April 28, 2016 Office of the Chief Accountant 100 F Street, NE USA Ladies and Gentlemen: We have read the statements regarding our firm contained in Items 4.01 and 4.02 of Form 8-K of Skystar Bio-Pharmaceutical Company dated and filed on April 6, 2016, and are in agreement with those statements. We hereby] []
[PRIVATE & CONFIDENTIAL Our Ref: SCH 1623/SS/KK/A18/CH0589/16 April 28, 2016 Office of the Chief Accountant 100 F Street, NE USA Ladies and Gentlemen: We have read the statements regarding our firm contained in Items 4.01 and 4.02 of Form 8-K of Skystar Bio-Pharmaceutical Company dated and filed on April 6, 2016, and are in agreement with those statements. We hereby] []
[Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 56,906,561 common shares as of December 31, 2015 ¨ x ¨ x x ¨ x ¨ o Large accelerated filer x Accelerated filer o Non-accelerated filer x U.S. GAAP International Financial] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 5. Sinovac Biomed Co., Ltd. (formerly known as Sinovac Zhong] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weidong Yin Chief Executive Officer] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Nan Wang Chief Financial Officer] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our reports dated April 25, 2016, with]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5) Total]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5) Total]
[FORM 10-K (Mark One) x December 31, 2015 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2015 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated April 14, 2016 relating to the consolidated financial statements, which appears in the Annual Report on Form] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Ronghua Wang Chief Executive Officer EX-32.1 8 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Qinghua Liu Interim Chief Financial Officer EX-32.2 9 ex32-2.htm EX-32.2]
[FORM 10-K (Mark One) x December 31, 2015 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2015 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated April 14, 2016 relating to the consolidated financial statements, which appears in the Annual Report on Form] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Ronghua Wang Chief Executive Officer EX-32.1 8 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Qinghua Liu Interim Chief Financial Officer EX-32.2 9 ex32-2.htm EX-32.2]
[Sinovac Special Committee Engages Financial and Legal Advisors BEIJING, April 14, 2016 -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the independent special committee of the Company’s Board of Directors, formed to consider “going private” proposals received by the Company, has appointed yesterday Duff & Phelps (Duff &] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. Nan Wang Chief Financial Officer 6-K 1 v436960_6k.htm FORM 6-K]
[Sinovac Special Committee Engages Financial and Legal Advisors BEIJING, April 14, 2016 -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the independent special committee of the Company’s Board of Directors, formed to consider “going private” proposals received by the Company, has appointed yesterday Duff & Phelps (Duff &] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. Nan Wang Chief Financial Officer 6-K 1 v436960_6k.htm FORM 6-K]
